160 related articles for article (PubMed ID: 35513231)
1. Time-averaged DAS28 and HAQ predict cardiovascular disease in patients with rheumatoid arthritis: Data from KORONA registry.
Min HK; Kim HR; Lee SH; Kang KY; Park SH; Kwok SK
Joint Bone Spine; 2022 Oct; 89(5):105401. PubMed ID: 35513231
[TBL] [Abstract][Full Text] [Related]
2. Baseline bony erosions and time-averaged DAS28 predict discontinuation of TNF inhibitors in rheumatoid arthritis.
Min HK; Kim SH; Lee SH; Kim HR
Sci Rep; 2022 Nov; 12(1):19951. PubMed ID: 36402804
[TBL] [Abstract][Full Text] [Related]
3. Low disease activity (DAS28≤3.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study.
Arts EE; Fransen J; Den Broeder AA; van Riel PLCM; Popa CD
Ann Rheum Dis; 2017 Oct; 76(10):1693-1699. PubMed ID: 28606965
[TBL] [Abstract][Full Text] [Related]
4. Sex differences in clinical characteristics and their influence on clinical outcomes in an observational cohort of patients with rheumatoid arthritis.
Shin S; Park EH; Kang EH; Lee YJ; Song YW; Ha YJ
Joint Bone Spine; 2021 May; 88(3):105124. PubMed ID: 33346105
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Disease Activity Score in 28 joints with ESR (DAS28), Clinical Disease Activity Index (CDAI), Health Assessment Questionnaire Disability Index (HAQ-DI) & Routine Assessment of Patient Index Data with 3 measures (RAPID3) for assessing disease activity in patients with rheumatoid arthritis at initial presentation.
Kumar BS; Suneetha P; Mohan A; Kumar DP; Sarma KVS
Indian J Med Res; 2017 Nov; 146(Supplement):S57-S62. PubMed ID: 29578196
[TBL] [Abstract][Full Text] [Related]
6. The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients.
Arts EE; Fransen J; den Broeder AA; Popa CD; van Riel PL
Ann Rheum Dis; 2015 Jun; 74(6):998-1003. PubMed ID: 24458537
[TBL] [Abstract][Full Text] [Related]
7. Not all moderate disease is the same - Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity.
Pan Y; Norton S; Gwinnutt JM; Kearsley-Fleet L; Symmons DPM; Lunt M; Young A; ; Hyrich KL; Verstappen SMM
PLoS One; 2019; 14(5):e0215999. PubMed ID: 31107887
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported Outcomes as Predictors of Change in Disease Activity and Disability in Early Rheumatoid Arthritis: Results from the Yorkshire Early Arthritis Register.
Twigg S; Hensor EMA; Emery P; Tennant A; Morgan AW;
J Rheumatol; 2017 Sep; 44(9):1331-1340. PubMed ID: 28668806
[TBL] [Abstract][Full Text] [Related]
9. Doppler ultrasound impacts response to intravenous tocilizumab in rheumatoid arthritis patients.
Morris NT; Brook J; Ben-Artzi A; Martin W; Kermani TA; Avedikian-Tatosyan L; Karpouzas G; Nagam H; Navarro G; Choi S; Taylor MB; Elashoff D; Kaeley GS; Ranganath VK
Clin Rheumatol; 2021 Dec; 40(12):5055-5065. PubMed ID: 34269927
[TBL] [Abstract][Full Text] [Related]
10. In early arthritis patients, high HAQ at baseline and DAS28 at three months predict suboptimal outcomes at two years: a retrospective cohort study.
Fanouriakis A; Papalopoulos I; Gergianaki I; Spyrou G; Erden A; Rapsomaniki P; Terizaki M; Avgoustidis N; Repa A; Kougkas N; Bertsias G; Boumpas DT; Sidiropoulos PI
Clin Exp Rheumatol; 2018; 36(5):806-813. PubMed ID: 29533750
[TBL] [Abstract][Full Text] [Related]
11. HAQ score is an independent predictor of sustained remission in patients with rheumatoid arthritis.
Lee KE; Choi SE; Xu H; Kang JH; Park DJ; Lee SS
Rheumatol Int; 2017 Dec; 37(12):2027-2034. PubMed ID: 28956118
[TBL] [Abstract][Full Text] [Related]
12. Mapping health assessment questionnaire disability index (HAQ-DI) score, pain visual analog scale (VAS), and disease activity score in 28 joints (DAS28) onto the EuroQol-5D (EQ-5D) utility score with the KORean Observational study Network for Arthritis (KORONA) registry data.
Kim HL; Kim D; Jang EJ; Lee MY; Song HJ; Park SY; Cho SK; Sung YK; Choi CB; Won S; Bang SY; Cha HS; Choe JY; Chung WT; Hong SJ; Jun JB; Kim J; Kim SK; Kim TH; Kim TJ; Koh E; Lee H; Lee HS; Lee J; Lee SS; Lee SW; Park SH; Shim SC; Yoo DH; Yoon BY; Bae SC; Lee EK
Rheumatol Int; 2016 Apr; 36(4):505-13. PubMed ID: 26849891
[TBL] [Abstract][Full Text] [Related]
13. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Ma M; Walker D; Heslin M; Patel A; Kingsley G
Health Technol Assess; 2014 Oct; 18(66):i-xxiv, 1-164. PubMed ID: 25351370
[TBL] [Abstract][Full Text] [Related]
14. Costs in Relation to Disability, Disease Activity, and Health-related Quality of Life in Rheumatoid Arthritis: Observational Data from Southern Sweden.
Wallman JK; Eriksson JK; Nilsson JÅ; Olofsson T; Kristensen LE; Neovius M; Geborek P
J Rheumatol; 2016 Jul; 43(7):1292-9. PubMed ID: 27252420
[TBL] [Abstract][Full Text] [Related]
15. Influence of pain score measured by a visual analog scale (PS-VAS) on the Health Assessment Questionnaire Disability Index and 28-joint Disease Activity Index with C-reactive protein in rheumatoid arthritis patients.
Yoshii I; Chijiwa T; Sawada N
Int J Rheum Dis; 2018 Nov; 21(11):1955-1961. PubMed ID: 30175554
[TBL] [Abstract][Full Text] [Related]
16. The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry.
Shadick NA; Gerlanc NM; Frits ML; Stolshek BS; Brady BL; Iannaccone C; Collier D; Cui J; Mutebi A; Weinblatt ME
Clin Rheumatol; 2019 Nov; 38(11):3081-3092. PubMed ID: 31353421
[TBL] [Abstract][Full Text] [Related]
17. Clinical performance of rheumatoid arthritis impact of disease score: a real-life evidence from the multicenter nationwide registry BioStaR.
Melikoglu MA; Ataman S; Bodur H; Cay HF; Capkin E; Akgul O; Cevik R; Gogus F; Kamanli A; Yurdakul FG; Gurer G; Yagci I; Rezvani A; Duruoz MT; Sunar I
Rheumatol Int; 2021 Nov; 41(11):1971-1978. PubMed ID: 34559275
[TBL] [Abstract][Full Text] [Related]
18. Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study.
Hirata S; Saito K; Kubo S; Fukuyo S; Mizuno Y; Iwata S; Nawata M; Sawamukai N; Nakano K; Yamaoka K; Tanaka Y
Arthritis Res Ther; 2013 Sep; 15(5):R135. PubMed ID: 24286472
[TBL] [Abstract][Full Text] [Related]
19. Treatment response and several patient-reported outcomes are early determinants of future self-efficacy in rheumatoid arthritis.
Doumen M; De Cock D; Pazmino S; Bertrand D; Joly J; Westhovens R; Verschueren P
Arthritis Res Ther; 2021 Oct; 23(1):269. PubMed ID: 34706771
[TBL] [Abstract][Full Text] [Related]
20. Predictors of Remission or Combined Remission and Low Disease Activity in Rheumatoid Arthritis Patients in Taiwan: A Prospective Cohort Study.
Tsai PH; Fang YF; Chen YF; Chen CC; Chiang WY; Chang CT; Huang YJ; Liou LB
J Clin Med; 2024 Apr; 13(9):. PubMed ID: 38731049
[No Abstract] [Full Text] [Related]
[Next] [New Search]
